Automate Your Wheel Strategy on GRFS
With Tiblio's Option Bot, you can configure your own wheel strategy including GRFS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GRFS
- Rev/Share 10.8115
- Book/Share 12.6498
- PB 0.8916
- Debt/Equity 1.7142
- CurrentRatio 2.6564
- ROIC 0.0264
- MktCap 6337189976.5612
- FreeCF/Share 0.9414
- PFCF 9.8941
- PE 27.3935
- Debt/Assets 0.4712
- DivYield 0
- ROE 0.0338
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | GRFS | Morgan Stanley | -- | Overweight | -- | -- | Feb. 12, 2025 |
News
Grifols (GRFS) Is Up 2.47% in One Week: What You Should Know
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Grifols (GRFS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Is Grifols (GRFS) Stock Undervalued Right Now?
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
GRFS vs. STVN: Which Stock Is the Better Value Option?
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.
Read More
Grifols: If This Works Out, It Has Massive Upside
Published: May 22, 2025 by: Seeking Alpha
Sentiment: Positive
Grifols offers compelling long-term upside, with potential returns exceeding 200% as the company recovers and grows earnings. Recent Q1 2025 results confirm strong operational recovery: top-line growth, improved margins, and significant debt reduction, supporting my continued conviction. The primary risk is high leverage, but ongoing cash flow improvements and no dividend payout allow to focus on deleveraging, with dividend restoration likely by 2026.
Read More
GRFS or NBIX: Which Is the Better Value Stock Right Now?
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Positive
Grifols remains a strong long-term investment due to its leading position in the plasma industry and improving financial fundamentals, despite short-term volatility and lack of a dividend. The company's revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential for future profitability. Grifols' valuation is attractive, with a potential upside to €20/share, driven by EPS growth and market expansion in plasma-derived products.
Read More
About Grifols, S.A. (GRFS)
- IPO Date 2011-06-02
- Website https://www.grifols.com
- Industry Drug Manufacturers - General
- CEO Mr. Jose Ignacio Abia Buenache
- Employees 23833